Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 3, 2015, Pages 435-444

  Baldelli, Sara ^a   Cattaneo, Dario ^a   Giodini, Luciana ^b   Baietto, Lorena ^c   Di Perri, Giovanni ^c   D'Avolio, Antonio ^c   Clementi, Emilio ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d SCIENTIFIC INSTITUTE   (Italy)

Author keywords

antiepileptic drugs; dried plasma spots; high performance liquid chomatography

Indexed keywords

ANTICONVULSIVE AGENT; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; LAMOTRIGINE; MONOHYDROXYCARBAMAZEPINE; RUFINAMIDE; UNCLASSIFIED DRUG; ZONISAMIDE;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PLASMA; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; BLOOD; DRUG MONITORING; PROCEDURES; STANDARDS; VALIDATION STUDY;

ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRIED BLOOD SPOT TESTING; DRUG MONITORING; HUMANS; ULTRAVIOLET RAYS;

EID: 84923069908     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0472     Document Type: Article

References (36)

1. Landmark CJ, Johannessen SI. Safety aspects of antiepileptic drugs-focus on pharmacovigilance. Pharmacoepidemiol Drug Saf 2012;21:11-20.
2. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of non epileptic conditions. Nat Med 2004;10:685-92.
3. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004;6:57-75.
4. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-76.
5. Aldaz A, Ferriols R, Aumente D, Calvo MV, Farre MR, García B, et al. Pharmacokinetic monitoring of antiepileptic drugs. Farm Hosp 2011;35:326-39.
6. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharma-cokinet 2006;45:1061-75.
7. Krasowski MD. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel) 2010;3:1909-35.
8. Contin M, Riva R, Albani F, Perucca E, Baruzzi A. Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: interference with the 10, 11-epoxide metabolite. Ther Drug Monit 1985;7:46-50.
9. Roberts WL, Rainey PM. Interference in immunoassay measurements of total and free phenytoin in uremic patients: a reappraisal. Clin Chem 1993;39:1872-7.
10. Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004;42:1228-55.
11. Parant F, Bossu H, Gagnieu MC, Lardet G, Moulsma M. Cross-reactivity assessment of carbamazepine-10, 11-epoxide, oxcarbazepine, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassays: PETINIA and EMIT 2000. Ther Drug Monit 2003;25:41-5.
12. Subramanian M, Birnbaum AK, Remmel RP. High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit 2008;30:347-56.
13. Shibata M, Hashi S, Nakanishi H, Masuda S, Katsura T, Yano I. Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. Biomed Chroma-togr 2012;26:1519-28.
14. Kim KB, Seo KA, Kim SE, Bae SK, Kim DH, Shin JG. Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spec-trometry. J Pharm Biomed Anal 2011;56:771-7.
15. Contin M, Mohamed S, Candela C, Albani F, Riva R, Baruzzi A. Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lam-otrigine, oxcarbazepinemonohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:461-5.
16. Heideloff C, Bunch DR, Wang S. A novel HPLC method for quantification of 10 antiepileptic drugs or metabolites in serum/plasma using a monolithic column. Ther Drug Monit 2010;32:102-6.
17. Mazzucchelli I, Rapetti M, Fattore C, Franco V, Gatti G, Perucca E. Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. Anal Bioanal Chem 2011;401:1013-21.
18. Baietto L, Simiele M, D'Avolio A. How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring? Bioanalysis 2014;6:425-7.
19. D'Avolio A, Simiele M, Siccardi M, Baietto L, Sciandra M, Bonora S. HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J Pharm Biomed Anal 2010;52:774-80.
20. Baietto L, D'Avolio A, Marra C, Simiele M, Cusato J, Pace S, et al. Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. J Antimicrob Chemother 2012;67:2645-9.
21. Baietto L, D'Avolio A, Pace S, Simiele M, Marra C, Ariaudo A, et al. Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. J Pharm Biomed Anal 2014;88:66-70.
22. Baietto L, D'Avolio A, Ariaudo A, Corcione S, Simiele M, Cusato J, et al. Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Analyt Technol Biomed Life Sci 2013;936:42-7.
23. Shah NM, Hawwa AF, Millership JS, Collier PS, McElnay JC. A simple bioanalytical method for the quantification of antiepi-leptic drugs in dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci 2013;923-924:65-73.
24. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychia-try 2011;44:195-235.
25. FDA Guidance for Bioanalytical Methods Validation for Human Studies. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001. Available from: http://www.fda.gov/down-loads/Drugs/Guidances/ucm070107.pdf. Accessed December 2013.
26. Martin RF. General Deming regression for estimating systematic bias and its confidence interval in method-comparison studies. Clin Chem 2000;46:100-4.
27. Van Dobben de Bruyn CS. Cumulative sum tests: theory and practice. In: Griffin K, editor. Statistics. New York: Hafner, 1968:1-45.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
29. Dewitte K, Fierens C, Stöckl D, Thienpont LM. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. Clin Chem 2002;48:799-801.
30. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60.
31. Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, et al. Pharmacokinetic variability of four newer antie-pileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedica-tion. Ther Drug Monit 2012;34:440-5.
32. Reimers A, Skogvoll E, Sund JK, Spigset O. Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions. Eur J Clin Pharmacol 2007;63:687-92.
33. Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, et al. Effect of age and comedication on levetiracetam pharma-cokinetics and tolerability. Epilepsia 2007;48:1351-9.
34. Salih MR, Bahari MB, Shafie AA, Hassali MA, Al-Lela OQ, Abd AY, et al. Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy. Epilepsy Res 2013;104:151-7.
35. Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis 2009;1:205-20.
36. Hagan AS, Jones DR, Agarwal R. Use of dried plasma spots for the quantification of iothalamate in clinical studies. Clin J Am Soc Nephrol 2013;8:909-14.